Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

ClinicalTrials.gov ID: NCT03587272

Public ClinicalTrials.gov record NCT03587272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).

Study identification

NCT ID: NCT03587272
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Robert Nickel; Other
Enrollment: 100 participants

Conditions and interventions

Conditions

Sickle Cell Disease

Interventions

Alemtuzumab, low dose total body irradiation, Sirolimus Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 25 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 17, 2018 (Actual)
Primary completion: Nov 2030 (Estimated)
Completion: Nov 2030 (Estimated)
Last update posted: Mar 10, 2026

2018 – 2030

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Children's National Health System	Washington D.C.	District of Columbia	20010	Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	60611	Recruiting
Columbia University	New York	New York	10032	Recruiting
Levine Children's Hospital	Charlotte	North Carolina	28203	Recruiting
Nationwide Children's Hospital	Columbus	Ohio	43205	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03587272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 10, 2026 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03587272 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →